News Sentiment

TSHA sentiment intelligence

Taysha Gene Therapies Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.96 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

89/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.0% over one week, -7.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 89/100 classification
One-week reaction -6.0% Price reacting lower
Trend fit Trend active -7.2% over four weeks
Fair value 95.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 9
TradingView 8
Investing.com 5
GlobeNewswire 4
simplywall.st 3
MT Newswires 3
Simply Wall Street 3

Event Lens

What the news is about

Classified themes
Market update 51
Earnings 12
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Investing.com Nigeria Direct company coverage

Taysha Gene Therapies president sells $1.25m in stock By Investing.com

Taysha Gene Therapies' President and Head of Research & Development, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026, as part of a pre-planned trading strategy. This sale occurred while TSHA shares have surged 149% over the past year, th

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 22:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

Taysha Gene Therapies president sells $1.25m in stock

The President and Head of Research & Development at Taysha Gene Therapies, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale follows a significant 149% surge in TSH

Tone
Negative 38/100
Event
Market update
Published
11 Jul 2026 10:40
Source
Investing.com
GuruFocus Direct company coverage

Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA)

Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction increased his total sales over the past year to 1,343,276 shares, with no purchases. The stock is currently

Tone
Negative 26/100
Event
Market update
Published
11 Jul 2026 10:40
Source
GuruFocus
Simply Wall Street Direct company coverage

Taysha Gene Therapies (TSHA) Could Be 49% Below Fair Value After Russell Index Drop

Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, yet its share price has shown strong recent performance. According to a common valuation model, the stock is currently undervalued by 48.9% at $6.57 compared to a fair value of $12.85, driven by progr

Tone
Positive 75/100
Event
Market update
Published
10 Jul 2026 23:10
Source
Simply Wall Street
Stock Titan Direct company coverage

Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan

Nagendran Sukumar, President and Head of R&D of Taysha Gene Therapies (NASDAQ: TSHA), sold 200,000 shares of common stock on July 10, 2026, at a weighted average price of $6.24 per share. This sale was conducted under a pre-established Rule 10b5-1 trading plan adopted in June 202

Tone
Negative 36/100
Event
Market update
Published
10 Jul 2026 23:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 144 Taysha Gene Therapies For: 10 July By Investing.com

This article from Investing.com reports that a Form 144 was filed for Taysha Gene Therapies on July 10th. Form 144 is a notice of the intent to sell restricted securities. The article provides no further details about the filing but includes a stock market quote for TSHA, which w

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:34
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies

A Taysha Gene Therapies (TSHA) shareholder, Sukumar Nagendran, has filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after July 10, 2026, with an estimated market value of $1,298,000. Nagendran previously sold 200,000 shares for $831,300 within the la

Tone
Negative 41/100
Event
Market update
Published
10 Jul 2026 20:10
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G

Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction adds to a pattern of 11 insider sells and no buys over the past year. With the stock trading at $6.24 and a

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:01
Source
GuruFocus
Simply Wall Street Direct company coverage

Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative?

Taysha Gene Therapies (TSHA) was recently removed from several Russell indices, coinciding with the release of new long-term clinical data for its TSHA-102 Rett syndrome gene therapy. This article examines how these events impact the company's investment narrative, focusing on ne

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 09:40
Source
Simply Wall Street
Investing.com Direct company coverage

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress

Citizens reiterated a Market Outperform rating and an $11.00 price target for Taysha Gene Therapies (NASDAQ:TSHA) based on progress in its TSHA-102 program for Rett Syndrome. The firm remains optimistic ahead of pivotal data and regulatory feedback expected in early 2027, noting

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 14:11
Source
Investing.com
Sahm Direct company coverage

Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue

Taysha Gene Therapies (TSHA) reported positive early results from its REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome, showing a 100% responder rate and durable functional improvements with a favorable safety profile. The company is accelerating commercial manufacturing prep

Tone
Positive 72/100
Event
Earnings
Published
01 Jul 2026 20:40
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA

This page from TradingView provides financial information for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates market data and various navigational links related to financial tools and commun

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Taysha Gene Therapies, Inc. – BOATS:TSHA

This page provides financial data, specifically the Enterprise Value to EBITDA forward, for Taysha Gene Therapies, Inc. (TSHA). It highlights that the information is presented without active trading data, indicating a market closed or no-trade status at the time of viewing. The c

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 06:30
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA

This article provides a brief mention of the "Price to sales forward" metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA). It appears to be a financial data point from TradingView, indicating a period value and changes but without specific numerical details in the snippet provi

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Taysha Gene Therapies, Inc. – BOATS:TSHA

The article focuses on the "Price to sales forward" metric for Taysha Gene Therapies, Inc. (TSHA), which is listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Taysha Gene Therapies, Inc. – NASDAQ:TSHA

This article provides access to the "Price to book forward" financial metric for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) on the TradingView platform. It details how users can find this information within the financial section of TSHA's profile, emphasizing data provided by ICE

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Taysha Gene Therapies, Inc. – BOATS:TSHA

This article provides financial information for Taysha Gene Therapies, Inc. (TSHA) on the TradingView platform. It specifically looks at the company's forward price-to-earnings ratio. The content also lists various features and resources available on TradingView for financial ana

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 01:11
Source
TradingView
Simply Wall Street Direct company coverage

Rett Data and $200 Million Raise Might Change The Case For Investing In Taysha (TSHA)

Taysha Gene Therapies recently completed a $200 million equity raise and released encouraging longer-term data from its REVEAL trial for TSHA-102 in Rett syndrome patients, showing durable functional gains and a good safety profile. Despite being delisted from some Russell indice

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 12:11
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 3000E Growth Benchmark

Taysha Gene Therapies, Inc. (NasdaqGS:TSHA) has been removed from the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focusing on AAV-based gene therapies for severe central nervous system monogenic diseases, with its lead program TSHA-102 targe

Tone
Negative 30/100
Event
Market update
Published
29 Jun 2026 04:31
Source
www.marketscreener.com
Investing.com Direct company coverage

Taysha Gene Therapies launches $200 million stock offering

Taysha Gene Therapies, a clinical-stage biotechnology company, has initiated an underwritten public offering of common stock and pre-funded warrants valued at $200 million. This move follows a significant 189% gain in its shares over the past year, although the stock appears over

Tone
Negative 34/100
Event
Market update
Published
25 Jun 2026 20:41
Source
Investing.com
GlobeNewswire Direct company coverage

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies announced multiple presentations at the 2026 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, showcasing its TSHA-102 gene therapy program. The presentations will cover safety and efficacy data from the REVEAL Part A Phase 1/2

Tone
Positive 75/100
Event
Market update
Published
25 Jun 2026 20:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Taysha lines up TSHA-102 data on Rett syndrome at June 29 meeting

Taysha Gene Therapies (Nasdaq: TSHA) will present multiple updates on its TSHA-102 program for Rett syndrome at the 2026 IRSF Rett Syndrome Scientific Meeting from June 29 to July 1, 2026. The presentations will include longer-term REVEAL Part A clinical data, natural history ins

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Taysha Gene Therapies Prices Equity Offering for ~$187.4 Million Net, Grants 5 Million Share Option

Taysha Gene Therapies announced an equity offering to sell over 33 million shares and pre-funded warrants at $6.00 per share, expecting to net approximately $187.4 million. The company has also granted underwriters an option to purchase up to 5 million additional shares, which co

Tone
Positive 67/100
Event
Market update
Published
25 Jun 2026 20:10
Source
TradingView